Therapeutic

NanoPass’ MicronJetTM Technology has been used to administer over 30,000 injections to approximately 7,500 patients in over 60 completed and ongoing clinical trials (as of December 2021) in various clinical applications including:

  • Vaccines
  • Immunotherapy (cancer, allergy, and type 1 diabetes mellitus)
  • Systemic delivery (insulin and adalimumab)

Intradermal Vaccination

Our extensive clinical trials have shown improved immunogenicity and dose sparing over both intramuscular and subcutaneous delivery, as well as over intradermal delivery using the Mantoux technique.

MicronJetTM was proven to significantly reduce vaccine doses and improve immunogenicity

Intradermal vaccine delivery has been repeatedly shown to allow significant dose sparing when compared to conventional administration methods**

**Darin Zehrung et al. intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine 31 (2013) 3392-3395

Research shows that by harnessing the robust immune system of the skin, intradermal delivery with MicronJetTM can achieve better immunological results than intramuscular and subcutaneous delivery, with lower doses.

intradermal delivery with MicronJetTM can achieve better immunological results than intramuscular and subcutaneous delivery, with lower doses.

Our extensive clinical trials have shown improved immunogenicity and dose sparing over both intramuscular and subcutaneous delivery, as well as over intradermal delivery using the Mantoux technique.

MicronJetTM – Hollow microneedles for intradermal injection

  • An easy-to-use, consistent and efficient intradermal needle solution for practically painless delivery of drugs and vaccines
  • Demonstrated improved immunogenicity and/or dose sparing over subcutaneous and intramuscular delivery in clinical studies
  • Demonstrated improved immunogenicity and/or potency over other intradermal devices in clinical studies
  • Supported by extensive clinical experience

Improved Immunogenicity and dose sparing over subcutaneous and intramuscular delivery

The skin is one of the most potent immune organs of the body, naturally evolved for fighting pathogens However, injecting vaccines into the skin with a regular needle (using the Mantoux technique) is technically difficult.

The easy-to-use MicronJetTM has demonstrated:

  • Improved immunogenicity to full-dose vaccines (seasonal influenza, zoster, HBV)
  • Significant dose sparing (4-40% of the dose) with various vaccines (seasonal and pandemic influenza, zoster, polio)
  • Adjuvant sparing in seasonal influenza

Improved immunogenicity/potency over other intradermal devices

Clinical trials have shown superior clinical outcomes of the MicronJetTM, over other intradermal delivery devices

  • Improved immunogenicity over intradermal delivery using the Mantoux technique attributed to the shallowness and consistency of injection3
  • Better potency over Intanza9®, delivering the same results with one third of the dose

Numerous trials

In addition to global commercial sales, NanoPass’ MicronJetTM Technology has been used to administer over 30,000 injections to approximately 7,500 patients in over 60 completed and ongoing clinical trials (as of December 2021).  The studies, conducted on subjects ranging in age from 6-week-old infants to 95 years in North America, Europe, Israel, Hong Kong, Brazil, Bangladesh and Japan, represent one of the industry’s most comprehensive database on intradermal delivery.

Extensive Clinical Experience

Intradermal vaccine delivery has been repeatedly shown to allow significant dose sparing when compared to conventional administration methods such as intramuscular and subcutaneous administration. The dermis and epidermis of the human skin are rich in antigen-presenting cells, such as Langerhans cells and dendritic cells, which play a critical role in the induction of immune responses. Injection of vaccines into these layers delivers antigens closer to these cells thus smaller doses of antigen might induce an equivalent immune response to the standard dose*.

*Darin Zehrung et al. Intradermal delivery for vaccine dose sparing: Overview of current issues. Vaccine 31 (2013) 3392– 3395

Validated Benefits

  • MicronJetTM has demonstrated a superior immune response with full dose and equivalence or a trend for superiority with lower doses (4-40%)

Skin tests

MicronJetTM provides an easy to use reliable and nearly painless method for skin tests (i.e. tuberculin skin test, allergy testing)

Tuberculin skin test (TST)

  • TST is widely used for the diagnosis of latent tuberculous infection
  • The Mantoux technique, the most commonly used for TST, is often difficult to perform reliably, affecting testing results and safety
  • A study comparing Mantoux technique to MicronJetTM for TST has shown that:
    • MicronJetTM was significantly less painful than the regular needle
    • MicronJetTM yielded significantly larger blebs than did conventional needles (consistent ID delivery)

Allergy testing

  • ID allergy testing is indicated when skin prick test (SPT) is negative and there is a strong clinical history for sensitization
  • ID testing is more sensitive, and detects immune responses to allergens with much greater accuracy
  • Absolute necessity to do ID testing, when the SPT is negative, for drugs and venoms

Preference

Users:

  • 94% found the device easier to use than a regular needle
  • 99% prefer the device over a regular N&S and would recommend its use

Patients:

  • >80% prefer to be vaccinated with the MicronJetTM and 75% prefer it for their children vaccination
  • 95% graded the injection as painless or less painful than a regular needle and 96% graded it is non or less intimidating than a regular needle

See all references